Introduction
============

According to the 'free radical hypothesis', the ageing process is a progressive accumulation of oxidative changes leading to disease and death \[[@b1], [@b2]\]. Studies also show age-related declines in both exogenous and endogenous antioxidant systems including vitamins C and E, glutathione (GSH) and antioxidant enzymes \[[@b3]--[@b6]\].

Intracellular thiols such as GSH are essential in maintaining the highly reduced environment inside the cell, whereas extracellular thiols also constitute an important component in antioxidant defence. Because the response of a cell to oxidative stress typically involves alterations in thiol content, plasma thiol concentrations are increasingly utilized for clinical and translational research involving oxidative stress \[[@b7]--[@b13]\], and for routine clinical diagnosis and monitoring of various human diseases and metabolic disorders \[[@b14]--[@b17]\]. Human plasma contains homocysteine (HcySH), cysteinylglycine (CysGlySH), cysteine (CysSH) and GSH as reduced thiols. These thiols are also found as low-molecular-mass (symmetrical) disulphides, *i.e.* homocystine (\[HcyS\]~2~), cystinilglycine (\[CysGlyS\]~2~), cystine (\[CysS\]~2~) and glutathione disulphide (GSSG). The measurement of these thiols in human plasma is of interest because most of them are metabolically related and disturbances of their concentrations can correspond to disorders of metabolism that occurs during ageing \[[@b18]\]. Ageing has recently been correlated to a decrease in human plasma GSH and CysGlySH and the concomitant increase in most oxidized forms of thiols as well as to a parallel increase in total Cys and total Hcy, probably due to an augmented efflux of these amino acids from various organs \[[@b19]\].

In human plasma, concentration of protein sulphydryl groups (PSHs) is in the 0.4--0.5 mM range, whereas that of low-molecular-mass thiols is in the 0.1--20 μM range \[[@b19], [@b20]\]. PSHs are common targets of oxidative modifications \[[@b21]--[@b23]\]. They are present as reduced thiols and/or mixed disulphides with HcySH, CysGlySH, CysSH and GSH (as a whole referred to as *S*-thiolated proteins) \[[@b19], [@b24], [@b25]\], through a reaction of *S*-thiolation, in which protein thiols form a mixed disulphide bond with low-molecular-mass thiols. This process plays both a regulatory and an antioxidant role, because it protects protein cysteinyl thiols against irreversible oxidation (*i.e.* further oxidation to sulphinic and sulphonic acids) \[[@b26]\] and also has a role in protein redox regulation \[[@b27]\].

There exist reports on the level of GSH, GSSG, malondialdehyde, protein carbonyls, 4-hydroxy-2,3-trans-nonenal, uric acid and the redox couples GSH/GSSG and CysSH/(CysS)~2~, as well as on antioxidant enzyme activities (superoxide dismutases and GSH peroxidases) in blood and plasma of healthy populations during ageing \[[@b6], [@b19], [@b28]--[@b32]\]. In these studies, tendencies for some parameters and also significant correlations were established, showing an increase in pro-oxidative effects and a decrease in antioxidative ones during ageing.

*S*-thiolated plasma proteins have been detected in healthy human beings, but increase in patients with cardiovascular diseases and in uremic patients on haemodialysis \[[@b33], [@b34]\]. Although increased protein *S*-thiolation is considered an *in vivo* marker of oxidative injury, scarce attention has been paid to the significance and quantification of *S*-thiolated proteins in blood plasma of healthy individuals during ageing. The purpose of the present study was to determine the relative amount of *S*-thiolated proteins (*i.e.* homocysteinylated, cysteinylglycinylated, glutathionylated and cysteinylated proteins) to the total protein thiols (*i.e.* the sum of protein sulphydryl groups and protein mixed disulphides with HcySH, CysGlySH, CysSH and GSH) in the plasma of healthy individuals aged 20 to 93 years. The results indicate a significant age-dependent decrease in reduced plasma PSHs, as well as an age-dependent increase in plasma concentrations of total *S*-thiolated proteins. In particular, we observed a little increase in *S*-homocysteinylated proteins as well as a large increase in *S*-cysteinylated proteins during ageing in healthy elderly individuals. The present results suggest that protection from oxidative damage by plasma thiol redox buffer becomes less efficient with age; this concerns not only decrease in plasma GSH \[[@b19], [@b28], [@b32]\] and increase in total Cys and total Hcy \[[@b19]\], but also cysteinylation and homocysteinylation of plasma proteins.

Materials and methods
=====================

Materials
---------

Monobromobimane (mBrB) was obtained from Calbiochem (La Jolla, CA, USA). Acivicin, 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB), *N*-ethylmaleimide (NEM) and all the other reagents used in this study were of analytical grade from Sigma-Aldrich (Milan, Italy). HPLC Spherisorb C18 column was purchased from Varian, Inc. (Palo Alto, CA, USA). HPLC separation was performed with an Agilent series 1100 HPLC equipped with fluorescence detector. Spectrophotometric analyses were performed with a Jasco V/530 instrument (Jasco Corporation, Tokyo, Japan).

Study participants
------------------

The study participants included 63 healthy individuals (38 females, 25 males) aged 20--93 years. Each participant declared not to have taken any medicine in the last 7 days, and was screened for diagnosed diseases. Individuals with diabetes or age-related cardiovascular, renal, pulmonary, hepatic or ocular disease were excluded, and none of them had any abnormality on physical examination nor in routine laboratory blood tests (serum glutamic oxaloacetic transaminase \[SGOT\], serum glutamic piruvate transaminase \[SGPT\], γ-glutamyltransferase \[γ-GT\], uraemia, creatininemia, erythrocytes sedimentation rate, blood cell number, platelet number, mean cellular volume, haematocrit, haemoglobin concentration, plasma protein concentration, albumin concentration). In particular, none of the individuals had any alterations in renal function (evaluated by the serum levels of creatinine and urea levels) nor in hepatic function (evaluated by activity of γ-GT and transaminases). Furthermore, the selection excluded not only individuals with acute infections or chronic diseases, but also excluded healthy individuals undergoing supplementation with antioxidant substances. The individuals were divided into four age groups ([Table 1](#tbl1){ref-type="table"}).

###### 

Characteristics of study groups

  Age groups     No. of individuals   Mean age   Females   Males
  -------------- -------------------- ---------- --------- -------
  20--40 years   18                   32.3       10        8
  41--60 years   18                   52.1       11        7
  61--80 years   16                   67.5       9         7
  81--93 years   11                   84.3       8         3

All human experimentation was conducted in conformance with the 'Principles for Research Involving Animals and Human Beings' and approved by the Local Ethical Committee of the University of Siena. Informed consent was obtained from all the individuals after the purpose and nature of the study had been explained.

Plasma collection and protein analysis
--------------------------------------

Blood samples were drawn in the morning after 10--12 hrs of starving from the antecubital vein, collected in plastic tubes containing K~3~EDTA, acivicin (50 μg/ml) and either mBrB or NEM to alkylate free sulphydryls. Samples were centrifuged at 10,000 ×*g* for 20 sec., at 4°C, for plasma separation; this rapid centrifugation was applied in order to avoid, as much as possible, the efflux of mBrB-GSH conjugate from red blood cells that could artefactually increase the measured levels of plasmatic GSH \[[@b35]\]. After plasma separation, *S*-thiolated proteins (*i.e.* the sum of *S*-homocysteinylated, *S*-cysteinylglycinylated, *S*-glutathionylated and *S*-cysteinylated proteins), total protein thiols (*i.e.* the sum of PSH +*S*-thiolated proteins; tPS), as well as CysSH, (CysS)~2~, HcySH and (HcyS)~2~, were measured by HPLC with fluorescence determination of the thiol-mBrB conjugate as previously reported \[[@b36]\]. The relative amounts of *S*-homocysteinylated (HcySSP), *S*-cysteinylglycinylated (CysGlySSP), *S*-glutathionylated (GSSP) and *S*-cysteinylated proteins (CysSSP) were calculated to the total amount of protein cysteinyl thiols (tPS, *i.e.* PSH +*S*-thiolated proteins). A summary of the procedures followed for accurate thiol/disulphide determination in human plasma is reported in [Fig. 1](#fig01){ref-type="fig"}.

![Schematic representation of the main analytical steps making the procedures we adopted for accurate thiol/disulphide determination in human plasma. mBrB: monobromobimane; NEM: *N*-ethylmaleimide; DTT: dithiothreitol; LMW: low molecular weight and RSSP: protein/thiol mixed disulphides.](jcmm0013-3131-f1){#fig01}

For determination of plasma levels of PSH, aliquots of blood samples were collected in evacuated plastic tubes containing only K~3~EDTA and acivicin (50 μg/ml) and then immediately centrifuged at 10,000 ×*g* for 20 sec., at 4°C; plasma was then stored at --80°C until the analyses were carried out. PSH determination was performed by spectrophotometry with DTNB as a titrating agent \[[@b37]\].

Statistical analysis
====================

For each age group, data are presented as the mean ± S.D. Statistical analysis among different age groups was performed by applying the one-way ANOVA test and the Bonferroni's test as multiple comparison method for all pairwise. Linear regression was performed by applying the Pearson product moment correlation test.

Results
=======

Human red blood cells contain approximately 500 times higher GSH concentration than plasma \[[@b26]\] so that minor haemolysis can result in erroneously high plasma GSH values. Furthermore, thiols can be lost by oxidation, which occurs with a half time of about 5 min. in plasma at room temperature \[[@b38]\]. Here, we have used a procedure that we have optimized to collect blood with minimal haemolysis, to prevent thiol oxidation and degradation during sample processing and to provide a specific and sensitive measure of plasma thiols \[[@b19], [@b35], [@b36], [@b39]\].

In all measured plasma samples, independently of age, mean values of PSH and *S*-thiolated proteins (*i.e. S*-cysteinylglycinylated +*S*-glutathionylated +*S*-homocysteinylated +*S*-cysteinylated proteins = RSSP) were 417.10 ± 29.23 μM and 182.9 ± 29.30 μM, respectively. On the basis of the total concentration for each low molecular mass thiol species, *i.e.* the concentration of reduced thiol + low-molecular-mass (symmetrical or unmixed) disulphides +*S*-thiolated proteins (*i.e.* protein/thiol mixed disulphides, RSSP), in all measured plasma samples, independently of age, tCys is present at the highest concentration (∼237 μM), with tCys \> tCysGly \> tHcy \> tGSH ([Table 2](#tbl2){ref-type="table"}). These results are in agreement with other reports \[[@b19], [@b20], [@b40]\]. In this context, it is worth noting that reported concentrations of low-molecular-mass disulphides presented in [Table 2](#tbl2){ref-type="table"} and throughout the manuscript are thiols measured after reduction of disulphides ([Fig. 1](#fig01){ref-type="fig"}); thus, what reported, for example, as GSSG is actually the sum of GSSG and asymmetrical disulphides, *i.e.* CysSSG, HcySSG and CysGlySSG. Hence, values reported by some authors, who discriminate between GSSG and asymmetrical disulphides \[[@b29]\], may be lower.

###### 

Plasma thiol levels in healthy individuals, independently of age

  Thiols         Plasma levels (μM)
  -------------- --------------------
  GSH            2.23 ± 0.78
  GSSG           1.23 ± 0.44
  GSSP           2.31 ± 1.18
  Total GSH      5.79 ± 1.80
  HcySH          0.23 ± 0.14
  (HcyS)~2~      1.71 ± 1.16
  HcySSP         9.33 ± 3.57
  Total Hcy      11.25 ± 4.44
  CysGlySH       2.04 ± 0.74
  (CysGlyS)~2~   5.69 ± 1.48
  CysGlySSP      11.96 ± 2.96
  Total CysGly   19.74 ± 3.93
  CysSH          9.96 ± 1.29
  (CysS)~2~      67.74 ± 13.59
  CysSSP         156.82 ± 28.44
  Total Cys      237.11 ± 36.61

Data are presented as the mean ± S.D.

[Figure 2](#fig02){ref-type="fig"} shows micromolar plasma concentrations of total protein thiols (tPS = PSH + RSSP) for each age group. The distribution of the total protein thiol levels during ageing ranged from about 589 to 618 μM. There was neither significant age-related tendency within this range nor significant difference between males and females (not shown). Differently, results illustrated in [Fig. 3](#fig03){ref-type="fig"} show age-dependent diminution in plasma concentration of PSH ([Fig. 3A](#fig03){ref-type="fig"}) as well as age-dependent increase in plasma concentrations of *S*-thiolated proteins ([Fig. 3B](#fig03){ref-type="fig"}). PSH declined with age from about 449 to 397 μM (--12%) ([Fig. 3A](#fig03){ref-type="fig"}), whereas the level of *S*-thiolated proteins increased with age from about 163 to 221 μM (+35%) ([Fig. 3B](#fig03){ref-type="fig"} and **C**). Results illustrated in [Fig. 3D](#fig03){ref-type="fig"} show age-dependent decrease in the plasma PSH/RSSP ratio from about 2.7 to 1.8, most, if not all, of decrease becoming evident over 60 years.

![Plasma levels of total protein thiols (tPS = reduced protein sulphydryl groups +*S*-thiolated proteins) for each age group. Data are means ± S.D.](jcmm0013-3131-f2){#fig02}

![Plasma levels of reduced protein sulphydryl groups (PSH) (A) and *S*-thiolated proteins (RSSP) (B, C) for each age group. (D): Shows the age-dependent decrease in the plasma reduced protein thiols/*S*-thiolated proteins (PSH/RSSP) ratio for each age group. Data are means ± S.D. Statistical significance (one-way ANOVA, *P* \< 0.05): (A): 21--40 *versus* 61--80 and *versus* 81--93; 41--60 *versus* 81--93; (B): 21--40 and 41--60 *versus* 81--93. (C): 21--40 *versus* 61--80 and 81--93; 41--60 *versus* 61--80 and 81--93.](jcmm0013-3131-f3){#fig03}

Measurements of *S*-cysteinylglycinylated and *S*-glutathionylated proteins, as the relative amount of *S*-thiolated proteins to total protein thiols and as a function of age, are illustrated in [Fig. 4A](#fig04){ref-type="fig"} and B, respectively. These *S*-thiolated proteins do not change significantly in correlation with age.

![Plasma levels of *S*-cysteinylglycinylated (CysGlySSP) (A), *S*-glutathionylated (GSSP) (B), *S*-homocysteinylated (HcySSP) (C), and *S*-cysteinylated (CysSSP) and (D) proteins for each age group. All values are expressed as the percentage to total plasma protein thiols. Data are means ± S.D. Statistical significance (one-way ANOVA, *P* \< 0.05): (C): 21--40 *versus* 81--93; 41--60 *versus* 61--80 and 81--93; 61--80 *versus* 81--93; (D): 21--40 *versus* 61--80 and 81--93; 41--60 *versus* 61--80 and 81--93.](jcmm0013-3131-f4){#fig04}

Measurements of *S*-homocysteinylated and *S*-cysteinylated proteins, as the relative amount of *S*-thiolated proteins to total protein thiols and as a function of age, are illustrated in [Fig. 4C](#fig04){ref-type="fig"} and **D**, respectively. An apparent, age-related minute increase (about 1%) was measured for *S*-homocysteinylated proteins, but variation of data also increased with age ([Fig. 4C](#fig04){ref-type="fig"}); however, the presence of *S*-homocysteinylated proteins, compared with that occurring in the youngest individuals (first group of age), increased by 25% and 75%, respectively, in the individuals aged 61--80 years and more than 80 years of age ([Fig. 4C](#fig04){ref-type="fig"}). Differently, a positive correlation was determined between *S*-cysteinylated proteins and the ageing process: results illustrated in [Fig. 4D](#fig04){ref-type="fig"} show a clear age-dependent increase, ∼8%, in plasma concentrations of *S*-cysteinylated proteins. In comparison with the group of the youngest individuals, the percentage increase in *S*-homocysteinylated proteins was about 26% and 35%, respectively, in the third and fourth group of age. Notwithstanding there is evidence for an association between *S*-cysteinylated proteins and age, there is also considerable variation among individuals of the same age group. However, the data reported in [Fig. 4C](#fig04){ref-type="fig"} and **D** clearly show that, until approximately 60 years of age, there is no significant association between *S*-homocysteinylated and *S-*cysteinylated proteins and age, whereas the ratio of *S*-homocysteinylated and *S-*cysteinylated proteins to total protein thiols increase with age over 60 years.

The CysSH/(CysS)~2~ redox couple quantitatively represents the largest pool of low-molecular-weight thiols and disulphides in plasma \[[@b41]\], and the mean value of plasma CysSH/(CysS)~2~ pool in human beings shows a significant oxidative shift between the third and the ninth decade of life \[[@b6], [@b42]\]. Results illustrated in [Fig. 5A](#fig05){ref-type="fig"} show that the plasma HcySH/(HcyS)~2~ ratio changes significantly during the whole age range. Differently, we measured only a slight age-dependent decrease (note the different scale range on the *y*-axis between [Fig. 5A](#fig05){ref-type="fig"} and **B**) in the plasma CysSH/(CysS)~2~ ratio ([Fig. 5B](#fig05){ref-type="fig"}).

![Effect of age on the homocysteine/homocystine, HcySH/(HcyS)~2~, (A) and the cysteine/cystine, CysSH/(CysS)~2~, (B) redox couple in healthy individuals. Data are means ± S.D.](jcmm0013-3131-f5){#fig05}

Discussion
==========

Major differences between cellular and extracellular compartments exist both in terms of the concentrations of sulphydryl/disulphide systems and their relative redox states \[[@b41], [@b43]\]. Within cells, the major low-molecular-weight sulphydryl/disulphide pool, GSH/GSSG, is principally in the reduced form. Differently, the CysSH/(CysS)~2~ pool, mainly in the disulphide form, quantitatively represents the largest pool of low-molecular-weight thiols and disulphides in plasma and the extracellular compartment on the whole. Therefore, intracellular proteins may be prevalently *S*-glutathionylated, whereas extracellular proteins may be predominantly *S*-cysteinylated. For example, although the small fraction of *S*-thiolated haemoglobin in red blood cells is *S*-glutathionylated \[[@b44]--[@b47]\], plasma proteins such as albumin are mainly *S*-cysteinylated \[[@b13], [@b26], [@b48]\].

In human plasma, concentration of PSHs is mostly due to cysteinyl residues of albumin, which reaches concentrations of more than 500 μM. As for the low-molecular-mass thiols, plasma concentration of GSH is generally in the range of 2--4 μM \[[@b19], [@b20], [@b26]\], CysSH is in the range of 8--10 μM and that of (CysS)~2~ is higher than 40 μM \[[@b29]\]. Although representing only a minor component as compared with protein cysteinyl thiols and free CysSH, GSH is the most extensively studied extracellular thiol/disulphide component in the human plasma during ageing \[[@b28], [@b32]\].

The present study shows no significant changes in the plasma concentrations of total protein thiols (PSH + RSSP) for each age group ([Fig. 2](#fig02){ref-type="fig"}). On the other hand, the age-related decrease in the plasma level of PSHs is accompanied by a significant increase in the concentration of *S*-thiolated proteins ([Fig. 3](#fig03){ref-type="fig"}). These data suggest that there is some increase in oxidative events targeting protein thiols throughout adult life, the phenomenon becoming clearly manifest as from 60--70 years. The pools of *S*-thiolated proteins differ in their relationships with age. There are scarce or no differences in the relative amount (as compared to total plasma protein thiols) of

*S*-cysteinylglycinylated and *S*-glutathionylated proteins between younger and older age groups of healthy individuals ([Fig. 4A](#fig04){ref-type="fig"} and **B**). On the contrary, *S*-homocysteinylated and *S*-cysteinylated proteins increase with age in healthy individuals ([Fig. 4C](#fig04){ref-type="fig"} and **D**). The age-related homocysteinylation is accompanied by a significative decrease in the plasma HcySH/(HcyS)~2~ ratio ([Fig. 5A](#fig05){ref-type="fig"}). In agreement with other reports \[[@b6], [@b42]\], our results suggest that the age-related cysteinylation is accompanied by a decrease in the plasma CysSH/(CysS)~2~ pool in healthy human beings ([Fig. 5B](#fig05){ref-type="fig"}).

The most abundant reduced sulphydryl group in plasma is that of human serum albumin (HSA), given its high concentrations. The single free cysteinyl thiol of HSA, Cys34, accounts for ∼80% of reduced thiols in human plasma and is an important scavenger of reactive oxygen and nitrogen species (ROS/RNS) in the vascular compartment, thus resulting to be a quantitatively important redox buffer of blood \[[@b49]--[@b51]\]. Although albumin circulates mostly (∼70%) in the reduced state, an important fraction (∼25%) of HSA circulates as mixed disulphides with low-molecular-mass thiols, mainly CysSH, likely *via* a stable sulphenic acid intermediate, whereas a small fraction (∼5%) is oxidized to higher, irreversible oxidation states (*i.e.* sulphinic and/or sulphonic acids) \[[@b50]--[@b52]\]. This balance between reduced and oxidized forms of HSA can shift in pathological states, and during ageing \[[@b51], [@b52]\]. Thus, decrease in plasma PSHs, as seen in aged groups ([Fig. 3A](#fig03){ref-type="fig"}), has important physiological implications. Reduced PSHs are important scavenger of ROS/RNS, thus homocysteinylation and cysteinylation of plasma protein sulphydryls that occur in healthy elderly individuals over the age of 60 years ([Fig. 4C](#fig04){ref-type="fig"} and D) could contribute to the decrease in the antioxidant capacity of plasma PSH. This involves an increased risk of irreversible oxidation (*i.e.* further oxidation to sulphinic and sulphonic acids) of protein thiols, which, because of the emerging data suggesting an important role for the extracellular thiol/disulphide redox environment in inducing and/or affecting intracellular signals that activate intracellular redox-sensitive pathways, such as cellular proliferation and matrix expression \[[@b41], [@b53], [@b54]\], may be critically important on signal transduction and transcription events that utilize proteins containing sulphydryl groups in reactive sites. Thus, the associated risk of adverse effects during ageing may increase ([Fig. 6](#fig06){ref-type="fig"}).

![Mean plasma PSH redox state becomes progressively oxidized with age after 60 years. Measurements of homocysteinylated and cysteinylated plasma proteins in healthy individuals show that little variation occurs among younger individuals but, after about 60 years, plasma reduced protein sulphydryl groups become progressively *S*-thiolated with age, contributing to the decrease in the antioxidant capacity of plasma. Thus, the associated risk of adverse effects during ageing may increase. In principle, *S*-thiolation in plasma protein thiols is reversible. Thus, if oxidative stress contributes to oxidant-mediated changes of ageing and age-related diseases, nutritional modulation or therapeutic interventions might provide a potentially useful strategy to restore redox state of human plasma.](jcmm0013-3131-f6){#fig06}

Protein-bound HcySH accounts for 70% to 80% of plasma total HcySH in healthy individuals \[[@b55], [@b56]\]. Homocysteinylation of accessible CysSH residues in different cellular and plasma proteins could alter their structure or function or both \[[@b57]\]. *In vitro* studies have shown that homocysteinylation of the Cys9 residue of annexin II, the endothelial cell surface docking protein for tissue plasminogen activator, inhibits binding \[[@b58]\]. HcySH also binds the fibrin binding domain of plasma fibronectin, inhibiting its ability to bind fibrin \[[@b59]\], as well as factor Va, making it resistant to inactivation by activated protein C \[[@b60]\]. Furthermore, the amyloidogenic protein transthyretin (pre-albumin) undergoes *S*-homocysteinylation at its single CysSH residue both *in vitro* and *in vivo*\[[@b61]\] and homocysteinylation of LDL induces an increase in oxidative damage and a decreased viability on human endothelial cells \[[@b62]\]. Intriguing, recent findings provide the first evidence of *S*-homocysteinylation of intracellular metallothionein, a ubiquitous intracellular zinc-chaperone and superoxide anion radical scavenger, which results in loss of protein function, thus suggesting a novel mechanism for disruption of intracellular zinc and redox homeostasis \[[@b63]\]. These studies thus provide novel evidence as to how HcySH may affect multiple cellular stress pathways \[[@b63]\].

Taken together, these studies suggest a possible link between increased oxidative stress, decrease in plasma GSH and PSH \[[@b19], [@b28], [@b32]\], increase in *S*-thiolated proteins and ageing, thus suggesting that antioxidant supplementation might be beneficial during ageing. On the other hand, a few clinical investigations have shown that CysSH supplementation exerts positive effects on certain functional and biochemical parameters, which become typically compromised in the course of ageing \[[@b64]\], supporting the hypothesis that oxidative changes may contribute to the ageing process.

In conclusion, several lines of evidence indicate that oxidative stress increases with age. Plasma redox values are dynamic indicators of the systemic balance between oxidative and antioxidant processes \[[@b6], [@b19], [@b41], [@b43]\]. The cross-talk among the various thiol pools in plasma (redox thiol status) has been proposed to be an element of the extracellular antioxidant defence system \[[@b6], [@b41], [@b65]\]. In this study, we show significant age-related changes of important biomarkers of oxidative stress in human plasma of healthy individuals. The increasing oxidative stress during ageing is accompanied by a decrease in reduced protein sulphydryls, and increase in *S*-homocysteinylated and *S*-cysteinylated proteins. This finding does not only underline the 'free radical hypothesis' of ageing, but is also important for the evaluation of further clinical studies with regard to basic (normal) values and with regard to the usage of age matched healthy control groups. In principle, analyses of reduced protein sulphydryls, *S*-homocysteinylated and *S*-cysteinylated protein levels in human plasma can be used to assess efficacy of intervention strategies against oxidative stress prior to or early after onset of clinical symptoms in ageing and age-related diseases.
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